Vertex Pharmaceuticals' unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led ...

Cardinal Health today reported fourth quarter fiscal year 2025 revenues of $60.2 billion, relatively flat compared to the ...

However, non-GAAP financials are still governed by the SEC. In fact, the SEC has taken action in the past against companies that it believes are being too aggressive with non-GAAP numbers.

Reports Q2 revenue $5.6M vs. $6M last year. “We’re pleased to report another quarter of sequential growth, highlighting the continued momentum of our business as we execute on our long-term strategy,” ...

Gain insights into CEVA, Inc.'s Q2 2025 earnings call, showcasing AI momentum, licensing growth, IoT leadership, and a positive outlook on revenue ...

Cash, cash equivalents, marketable securities and restricted cash as of June 30 totaled approximately $408.2M. Vlad Coric, Chairman and CEO of ...

Please note that the limited information that follows in this press release is a summary and is not adequate for making an ...

GAAP revenue for Q2 2025 was $161.1 million, falling short of analyst estimates of $164.5 million. Adjusted diluted EPS (non-GAAP) for Q2 2025 was $0.51, slightly above the consensus estimate of $0.50 ...

Key Points GAAP revenue of $20.5 million in Q2 2025 surpassed analyst expectations by 9.3%, despite a decline from the same period in 2024. Non-GAAP loss per share was $(0.01) in Q2 2025. Cash ...

Record non-GAAP operating margin of 24.5 percent increased 490 basis points quarter-over-quarter and 1,250 basis points year-over-year Free cash flow of $355.7 million or 20.4 percent of revenue ...

Published Aug 17, 2023 6:50am EDT -- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million 1 ---- FY 2023 Adjusted non-GAAP earnings per share expected to be $4.40 - $4.70 1 ...